MedTrace Logo

Bovine Intestinal Alkaline Phosphatase (bIAP) Modulating Rheumatoid Arthritis

NCT01416493 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2015-03-10

No results posted yet for this study

Summary

This is a proof of concept study asking if alkaline phosphatase injections can reduce acute inflammation in rheumatoid arthritis patients.

Conditions

  • Acute Rheumatoid Arthritis

Interventions

DRUG

s.c. injections of bovine intestinal Alkaline Phosphatase

daily subcutaneous treatment with two injections of 2000IU bIAP for three days

Sponsors & Collaborators

  • Aix Scientifics

    collaborator INDUSTRY

  • Alloksys Life Sciences B.V.

    lead INDUSTRY

Principal Investigators

  • Anthony Hammond, MD · Maidstone Hospital, Dept. Rheumatology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01416493 on ClinicalTrials.gov